Dover has entered into a definitive agreement to accumulate Malema Engineering Corp, a US designer and manufacturer of high-precision, mission-critical flow-measurement and control instruments for the biopharmaceutical, semiconductor and industrial sectors.
Malema’s products will increase Dover’s biopharma single-use production providing, which already contains Quattroflow pumps, CPC connectors, and em-tec flowmeters.
Based in Boca Raton, Florida, and with facilities in San Jose, California, Singapore, South Korea and India, Malema expects to generate roughly US$40 million–45 million in income during the full year 2022.
When the deal closes, Malema will turn into part of the PSG enterprise unit inside Dover’s Pumps & Process Solutions phase.
“We see a tremendous long-term growth opportunity in the bioprocessing industry driven by a robust and rising pipeline of efficient novel biologic medication, biosimilars, protein therapies, non-COVID mRNA vaccines, as nicely as budding cell & gene therapies,” says PSG’s president Karl Buscher. “Additionally, the growing adoption of extra efficient single-use production processes helps a sturdy outlook for our offerings of single-use components to end-customers. Sale ends soon imagine that pairing Malema’s expertise with our current portfolio of single-use pumps for biopharma processing will significantly improve the accuracy and value proposition of our options to our customers.”
“We are methodically constructing out our biopharma platform through proactive capability additions, new product growth, and opportunistic acquisitions of highly-attractive area of interest component applied sciences,” said Richard Tobin, president and CEO of Dover. “Malema represents a strategic and highly-complementary flow-control and sensing expertise and further strengthens our sensor portfolio with new proprietary technology. In Hidden to attractive biopharma functions, we count on robust growth in the semiconductor house on the capacity enlargement and re-shoring tailwinds.”
Share